About Mymee

Mymee is a leader in precision care and nutrition for individuals still struggling with significant, unpredictable symptoms associated with long COVID and autoimmune diseases like multiple sclerosis, lupus, Sjögren’s syndrome and rheumatoid arthritis.

Scientific publications indicate that any number of environmental triggers may worsen autoimmune symptoms. Unlike Celiac disease, where the known trigger is gluten, diseases like MS, lupus, Sjögren’s syndrome, RA and long COVID have multiple triggers that vary by individual. What is healthy for one person could harm another.

Mymee makes it possible for individuals to identify specific trigger-symptom correlations that are unique to their case so they can predict, lower and manage symptoms. Mymee combines technology, research and highly specialized long COVID and autoimmune disease coaches to guide health improvements backed by data and aligned to individual needs and preferences.  Mymee’s ‘n-of-1’ research matched over 150 unique symptoms to over 90 unique triggers and clinically tested over 50 types of interventions. Mymee also offers support through Emilyn, the #1 ranked app for individuals suffering from MS.

In 2022, Mymee joined NYCHBL’s Digital Health 100 as a women’s health company to watch and one of the most innovative health startups in New York. Mymee received the Platinum Award in the category of Precision Medicine from Juniper Research. Additionally, Mymee was nominated for the 2021 Annual Galien Foundation Awards and received an honorable mention in Fast Company‘s World Changing Ideas Awards.